LPCN Key Statistics, Chart & Performance
The current stock price of LPCN is 11.13 USD. In the past month the price increased by 203.27%. In the past year, price increased by 154.69%.
LPCN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LPCN. When comparing the yearly performance of all stocks, LPCN is one of the better performing stocks in the market, outperforming 99.08% of all stocks.
LPCN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LPCN. No worries on liquidiy or solvency for LPCN as it has an excellent financial health rating, but there are worries on the profitability.
LPCN Financial Highlights
Over the last trailing twelve months LPCN reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 168.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.06% | ||
| ROE | -38.72% | ||
| Debt/Equity | 0 |
LPCN Forecast & Estimates
8 analysts have analysed LPCN and the average price target is 7.01 USD. This implies a price decrease of -36.99% is expected in the next year compared to the current price of 11.13.
For the next year, analysts expect an EPS growth of -230.15% and a revenue growth -90.82% for LPCN
LPCN Ownership
LPCN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.38B |
Related stock screener links
About LPCN
Company Profile
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 16 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Company Info
LIPOCINE INC
675 S Arapeen Dr Ste 202
Salt Lake City UTAH 84108 US
CEO: Mahesh V. Patel
Employees: 16
Phone: 18019947383
LIPOCINE INC / LPCN FAQ
What does LIPOCINE INC do?
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 16 full-time employees. The company went IPO on 2014-03-21. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. The company is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
What is the stock price of LIPOCINE INC today?
The current stock price of LPCN is 11.13 USD. The price decreased by -1.15% in the last trading session.
Does LPCN stock pay dividends?
LPCN does not pay a dividend.
What is the ChartMill technical and fundamental rating of LPCN stock?
LPCN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for LIPOCINE INC?
The Revenue of LIPOCINE INC (LPCN) is expected to decline by -90.82% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
How many employees does LIPOCINE INC have?
LIPOCINE INC (LPCN) currently has 16 employees.
Can you provide the ownership details for LPCN stock?
You can find the ownership structure of LIPOCINE INC (LPCN) on the Ownership tab.